Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome
The publisher did not provide an abstract — full text is available via the link below.
The publisher did not provide an abstract — full text is available via the link below.